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OBJECTIVES We sought to optimize vascular endothelial growth factor (VEGF) treatment for therapeutic
angiogenesis in myocardial ischemia, we explored the efficacy of five different regimens.
BACKGROUND Although VEGF165 is one of the most potent pro-angiogenic growth factors, VEGF165
treatment for myocardial ischemia has been hampered by low efficacy and dose-limiting
hypotension after systemic or intracoronary delivery.
METHODS This study evaluated the effect of intravenous or intracoronary rhVEGF165 in the presence or
absence of nitric oxide (NO) synthase inhibition in a porcine model of chronic myocardial
ischemia. Forty-two Yorkshire pigs with chronically occluded left circumflex coronary arteries
were randomly assigned to receive 10 mg/kg of VEGF165: 1) rapid (40 min) intravenous
VEGF165 0.25 mg/kg/min, 2) slow (200 min) intravenous VEGF165 0.05 mg/kg/min, 3)
rapid intracoronary VEGF165 0.25 mg/kg/min, 4) rapid intracoronary VEGF165 0.25
mg/kg/min 1 nitro-L-arginine methyl ester hydrochloride (L-NAME) or 5) rapid vehicle
infusion.
RESULTS Intracoronary and intravenous VEGF165 induced hypotension. Intracoronary VEGF-induced
hypotension was blocked by L-NAME. Coronary angiography three weeks after treatment
showed improvement in collateral index in both intracoronary groups but not the intravenous
VEGF165 groups. Likewise, myocardial blood flow and microvascular function in the
ischemic territory improved in both intracoronary groups but not in the intravenous groups.
Global and regional myocardial function showed no significant improvements in any groups.
CONCLUSIONS Intracoronary infusion of VEGF165 significantly improves blood flow to the ischemic
myocardium. Concomitant administration of L-NAME inhibits VEGF-induced hypoten-
sion while most likely preserving VEGF-induced angiogenesis. Intravenous infusion of
VEGF165 was not effective in augmenting either myocardial flow or function in this model.
(J Am Coll Cardiol 2001;37:616–23) © 2001 by the American College of Cardiology
Various angiogenic growth factors, such as the fibroblast
growth factors FGF-2 (1) and FGF-1 (2), vascular endo-
thelial growth factor isoforms (VEGF)165 (3) and VEGF121
(4) are currently being evaluated in clinical trials as potential
therapeutic agents in patients with chronic myocardial
ischemia (see Ware and Simons for review [5]). In prior
studies, we and others have shown that continuous periad-
ventitial (6), atrial (7), intracoronary (IC) (8,9) or single-
bolus intracoronary (9,10) administration of VEGF165 in
animal models of chronic myocardial ischemia improves
regional blood flow and regional left ventricular (LV) wall
motion in the ischemic territory. However, recently com-
pleted Phase I clinical trials of intracoronary and intrave-
nous (IV) VEGF infusions demonstrated severe hypoten-
sion at relatively low doses, and a Phase II trial employing a
combination of intracoronary and intravenous VEGF deliv-
ery failed to show any benefit with regard to myocardial
function and perfusion at the doses used (3). The negative
results of this study raise a number of questions with regard
to VEGF165 efficacy as a therapeutic angiogenic agent and
the suitability of various modes of its delivery.
Systemic hypotension is the major acute side effect of
VEGF165 administration (10,11). Hypotension is primarily
mediated by VEGF-induced release of nitric oxide (NO)
(10–12) and therefore might be circumvented effectively by
pretreatment with an NO synthase inhibitor. On the other
hand, NO is essential for VEGF-induced angiogenesis, and
nitric oxide synthase (NOS) blockade may inhibit angio-
genic effects of VEGF therapy (13–15). Therefore, the
present study was designed to determine angiogenic efficacy
of intravenous or intracoronary VEGF delivery and to
explore the effect of pretreatment with an NO synthase
inhibitor, L-NAME, on hemodynamic and angiogenic
effects of VEGF therapy.
METHODS
Porcine model of chronic myocardial ischemia and treat-
ment protocol. Forty-two 30 to 35 lb male Yorkshire pigs
(Parsons Farm, Massachusetts) were selected for the study.
The study consisted of three phases as previously described
(6,9,16,17). For all procedures the animals were anesthe-
tized with ketamine 20 mg/kg and sodium thiopenthal
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10 mg/kg IV, intubated, mechanically ventilated and further
anesthetized with 1.5% to 2.5% isoflurane in room air.
Postoperatively, all animals received antibiotics for 48 h and
narcotic analgesics (buprenorphine 0.02 mg/kg i.m.) for
24 h and, after that, oral ketaprophen b.i.d. as needed. All
animals were cared for according to the National Institute of
Health Guidelines for the Care and Use of Laboratory
Animals, and the protocol was approved by the BIDMC
Institutional Animal Care Committee.
In the initial phase, an ameroid occluder (I.D. 2 to
2.5 mm, Research Instruments SW, Escondido, California)
was placed on the proximal left circumflex coronary artery
(LCX). Three weeks later, the animals were brought back
for cardiac catheterization using a standard femoral access.
A second 8F sheath (Avanti, Cordis, Miami, Florida) was
introduced in the right femoral vein for atrial pacing.
Heparin 100 U/kg was used for systemic anticoagulation.
Intra-arterial pressure and electrocardiogram were continu-
ously monitored and recorded. Selective angiography of the
left and right coronary arteries was performed to confirm
closure of the ameroid and to assess baseline angiographic
parameters. Baseline regional blood flow was measured by
intra-atrial colored microspheres. Two-dimensional echo-
cardiographic recording was obtained at rest and after 2 min
of atrial pacing at 170 beats/min to quantify global and
regional cardiac function. Following these studies, the
animals were randomly assigned to one of the following five
groups (n 5 8–9 for each group): 1) controls (saline infusion
with IV 40 U/kg heparin bolus), 2) IV rhVEGF165 infusion
0.25 mg/kg/min, 3) IV rhVEGF165 infusion 0.05 mg/kg/
min for 200 min, 4) IC rhVEGF165 infusion 0.25 mg/kg/
min and 5) IC rhVEGF165 infusion 0.25 mg/kg/min, after
10 mg/kg IV bolus of L-NAME (Sigma, St Louis, Mis-
souri). Except for group 3, infusions lasted for 40 min.
Hemodynamic parameters were recorded for 40 min fol-
lowing the completion of infusion.
Three weeks after initiation of therapy, the animals were
brought back for final evaluation with repeat coronary
angiography, myocardial blood flow determination and rest
and pacing stress echocardiography. After these studies,
animals were put to death, and the hearts were removed for
microsphere analyses.
Angiography: performance and analysis. Selective right
coronary and left coronary angiography was performed
using a 7-FR JR4 diagnostic angiography catheter (Cordis,
Miami, Florida) and Renografin (Squibb Diagnostics,
Princeton, New Jersey) contrast and were recorded using
cine angiography (General Electric, LU). The films were
read in a blinded manner by two experienced angiography
readers. Discordant readings were adjudicated by consensus
(10% of cases). Collateral index was rated using a semiquan-
titative approach as previously described (18): 0 5 no visible
collaterals, 1 5 faint filling of side branches of the main
epicardial vessel without filling the main vessel, 2 5 partial
filling of the main epicardial vessel, 3 5 complete filling of
the main vessel.
Myocardial blood flow. Colored microspheres (Dye Trac,
Triton Technologies, San Diego, California) were used for
blood flow determinations. Microspheres were injected
through a 7F JL4 diagnostic angiography catheter that was
advanced in a retrograde manner into the left atrium, with
its position confirmed by recording of an atrial pressure
wave.
At midstudy, 3 3106 blue microspheres and at final study
5 3 106 yellow (rest regional blood flow) and red (stress
flow) microspheres were injected over 30 s while a reference
blood sample was withdrawn from the femoral artery at
4 ml/min for 2 min. At the end of the study, the heart was
cut in five or six cross sections. From these cross sections,
photographic images were taken and digitized, and infarct
areas were morphometrically measured using Optimas 6.0
software. A 1-cm-thick cross section of the LV was taken at
mid-papillary level for microsphere analysis and was divided
in eight radial segments of equal size. Three segments
representing the LCX territory were further subdivided in
endocardial and epicardial sections. The tissue samples and
the reference blood samples were processed, and myocardial
blood flow was calculated as previously described (9).
Echocardiographic analysis of regional and global myo-
cardium. Transthoracic echocardiograms were performed
in all animals at rest and after 2 min of right atrial pacing
stress at 170 beats/min (7F bipolar pacing electrode NIBH,
CR BARD, Billerica, Massachusetts). Echocardiograms
were performed with a Hewlett-Packard Sonos 5500
(Hewlett-Packard, Andover, Massachusetts) sector scanner
equipped with a 4 MHz phased-array transducer. Two-
dimensionally guided M-mode tracings were recorded. An-
terior and posterior wall thickness and LV internal dimen-
sions were measured in standard fashion on at least three
consecutive beats and averaged using an off-line analysis
system (Cardiac Workstation, Freeland Systems, Louisville,
Colorado) by one observer blind to study group. Regional
function was assessed by systolic wall thickening in the
posterior (LCX territory) and anterior (left anterior de-
scending [LAD] territory) walls calculated as [%Th 5
(systolic thickness2diastolic thickness)/diastolic thick-
Abbreviations and Acronyms
ANOVA 5 analysis of variance
IC 5 intracoronary
IV 5 intravenous
LAD 5 left anterior descending artery
LCX 5 left coronary circumflex artery
L-NAME 5 Nv-nitro-L-arginine methyl ester
hydrochloride
LV 5 left ventricle, left ventricular
MANOVA 5 multivariate analysis of variance
NO 5 nitric oxide
NOS 5 nitric oxide synthase
SNP 5 sodium nitroprusside
VEGF 5 vascular endothelial growth factor
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ness 3 100]. %Th in LCX territory at each time point was
normalized to that in the LAD territory, and changes over
time were compared. Global function was assessed using
fractional shortening calculated as [FS 5 (diastolic LV
diameter2systolic LV diameter)/diastolic diameter 3 100].
Microvascular function studies. Microvascular studies on
vessels were prepared from the epicardial myocardium of the
LCX- and LAD-dependent territories (80 to 170 mm in
internal diameter and 1 to 2 mm in length) as previously
described (19). Responses to endothelium-dependent
receptor-mediated vasodilatory substances (ADP, 1 nm to
10 mm) and endothelium-independent agent sodium nitro-
prusside were tested after potassium chloride preconstric-
tion.
Administration of VEGF and L-NAME. The total
rhVEGF165 (Genentech, Inc, San Francisco, California)
dose delivered by IC infusion (pump: model 901, Harvard
Instruments, Dover, Massachusetts) was equally divided
between the RCA and the proximal LCX arteries (20 min
in each artery) using a 3F infusion catheter (Cordis Corp.).
In those animals in which the proximal LCX was too short
to stabilize the infusion catheter, rhVEGF165 was infused
into the proximal part of the LAD. IV rhVEGF165 was
infused through the ear vein. In the L-NAME group,
10 mg/kg L-NAME IV (Sigma, St Louis, Missouri) in
saline was injected 5 min before rhVEGF165.
Data representation and statistical analysis. All data are
given as mean 6 SEM unless indicated otherwise. As this
study was not powered for direct between group compari-
sons, paired t tests on continuous variables measured at mid-
and final study were performed for each experimental group.
For baseline variable comparison, analysis of variance
(ANOVA) (SPSS 7.5) with a Bonferroni correction was
applied. In addition, in the case of multiple measurements
per animal over time, such as the hemodynamic parameters,
a multivariate analysis of variance (MANOVA) with re-
peated measures and with treatment as the second indepen-
dent variable was used. Ordinal data, such as collateral index
scale, were analyzed using Kruskal Wallis and by the
Wilcoxon test for differences within the group over time
(i.e., final study vs. midstudy). A p value ,0.05 was
considered statistically significant.
RESULTS
Fifty-six animals underwent ameroid surgery, 14 (25%) died
before randomization for treatment. Forty-two animals
(control n 5 9, IV VEGF n 5 8, IC VEGF n 5 8, IC
VEGF 1 L-NAME n 5 9, IV VEGF slow infusion n 5
8) completed the study. The LCX was occluded at mid-
study in all animals.
Hemodynamic parameters. Both IV and IC VEGF infu-
sions caused a transient drop in mean arterial blood pressure
(MAP) that peaked at 10 to 15 min after the start of
infusion and ranged from 15.3 6 4.0 mm Hg in the 0.25
mg/kg/min IC group to 22.3 6 3.0 in the 0.05 mg/kg/min
IV group (26% reduction in MAP) (Table 1). Thus,
reducing the rate of infusion to 0.05 mg/kg/min did not
prevent hypotension. Pretreatment with L-NAME, how-
ever, effectively inhibited the decrease in MAP without
significantly augmenting the initial (pre-L-NAME) blood
pressure. In all groups, MAP returned to pretreatment
values in approximately 20 min after the end of the infusion
(data not shown). These changes in blood pressure were not
accompanied by any significant changes in the heart rate.
Coronary angiography. Complete angiography data were
missing from two animals. The collateral index at baseline
was similar for all groups (Kruskal Wallis, p 5 0.897). All
groups demonstrated a trend towards increased collateral-
ization as expected in this model. However, a significant
increase in left-to-left collateralization was observed only in
both IC groups (Fig. 1). At the same time, no right-to-left
(RCA 3 LCX) collateralization remained unchanged (not
shown). Thus, administration of VEGF into the left and
right coronary system resulted in a directional increase in
collateral circulation (left-to-left but not right-to-left col-
laterals), which was not inhibited by a single administration
of L-NAME.
Coronary blood flow. Regional blood flow to the LCX
and LAD territories at rest before the start of VEGF
infusion, and at rest and during stress three weeks after
treatment, was measured by colored microspheres. Baseline
flow to the normal part of the heart was similar in the
treatment groups (ANOVA, p 5 0.210) and did not change
significantly over time, with p-values ranging from 0.10 for
the IC VEGF group to 0.67 for the IV VEGF 0.05










(%) HR Change in HR
Control 8 89.7 6 8.0 1.2 6 0.8 1.4 6 1.1 111.5 6 9.5 –2.0 6 5.9
VEGF 0.05 i.v.
for 200 min
8 88.0 6 7.7 22.3 6 3.0* 25.6 6 2.8* 112.3 6 6.7 –10.1 6 5.1
VEGF 0.25 i.v. 9 73.6 6 5.9 21.3 6 4.8* 27.8 6 5.8* 106.4 6 8.4 –3.2 6 4.4
VEGF 0.25 i.c. 8 71.4 6 7.4 15.3 6 4.0 21.5 6 5.6 122.1 6 12.4 –17.1 6 10.9
VEGF 0.25 i.c. 1
L-NAME
9 79.7 6 7.5 5.9 6 2.2 9.0 6 3.8 104.0 6 9.6 15.8 6 7.9
*p , 0.05 vs control (Oneway, Bonferroni)
All values are means 6 sem.
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mg/kg/min group (Table 2). Rest flow increased signifi-
cantly in the IC VEGF group (Fig. 2, paired t test, p 5
0.006) and showed an upward trend in the IC VEGF 1
L-NAME group (p 5 0.122). Stress flow during the final
study was higher in the IC VEGF/L-NAME group (p 5
0.003) than in controls and showed a trend in the IC VEGF
group (p 5 0.06). The IV groups were no different from
controls with respect to change in rest flow over time or to
flow at stress.
Left ventricular function. To assess the effect of VEGF
therapy on global and regional LV function, M-mode and
two-dimensional echo recording were obtained at rest and
during pacing stress at mid-study and at the final study. Left
ventricular fractional shortening (FS) did not change in any of
the VEGF treated groups (Fig. 3). In contrast, in the control
group the LV FS decreased significantly (paired t test, p 5
0.002). At stress, the FS showed an upward trend in the IC
VEGF 1 L-NAME group only (paired t test, p 5 0.067). No
differences were found in FS over time at rest (MANOVA
with repeated measures, p 5 0.623 for the time effect and
0.640 for the time by treatment effect) or during stress (p 5
0.243 for the time effect and 0.149 for time by treatment).
Figure 1. Line plots of collateral index scores (see Methods) at treatment (mid) and three weeks after treatment (final).
Table 2. Regional Coronary Blood Flow (ml/g/min) in LAD and LCX Territory
Treatment
Basal Flow Final Flow Stress Flow (final)
LAD LCX p Value LAD LCX LAD LCX
Control 0.63 6 0.07 0.43 6 0.03 0.04 0.73 6 0.12 0.62 6 0.09 0.70 6 0.18 0.41 6 0.10
VEGF 0.05 i.v. for 200 min 0.74 6 0.06 0.67 6 0.08 0.03 0.79 6 0.11 0.80 6 0.14 0.77 6 0.12 0.54 6 0.10
VEGF 0.25 i.v. 0.86 6 0.05 0.67 6 0.09 0.07 0.95 6 0.18 0.96 6 0.20 1.19 6 0.49 0.50 6 0.13
VEGF 0.25 i.c. 0.89 6 0.20 0.58 6 0.07 0.07 1.09 6 0.12 1.12 6 0.21* 1.36 6 0.22 1.07 6 0.14
VEGF 0.25 i.c. 1 LNAME 1.05 6 0.20 0.57 6 0.09 0.03 0.98 6 0.11 0.90 6 0.16† 1.31 6 0.21 1.45 6 0.23‡
* p 5 0.006, compared with basal LCX flow. † p 5 0.122, compared with basal LCX flow. ‡ p 5 0.003, compared with stress flow in controls.
LAD 5 left anterior descending artery; LCX 5 left coronary circumflex artery.
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Regional ventricular function was measured as percent
systolic wall thickening in the ischemic (LCX, target) area
normalized for the septal (normal) area (TWT/NWT). At
baseline at rest, TWT/NWT ranged from 0.25 6 0.09 in
the IV VEGF 0.25 mg/kg/min group to 0.43 6 0.08 in the
VEGF1L-NAME group (ANOVA, p 5 0.614). During
pacing, TWT/NWT ranged from 0.04 6 0.11 in the
control group to 0.33 6 0.10 in the IC VEGF group
(ANOVA, p 5 0.282). No significant improvement was
noted from mid-study to final study in any group at rest or
stress (Fig. 4). Using MANOVA with repeated measures,
no differences in regional LV function were found between
the treatment groups at rest (p 5 0.955 and p 5 0.853 for
time effect and time by treatment effect respectively) or
during stress (p 5 0.165 and p 5 0.891 for time effect and
time by treatment effect).
Microvascular function. As expected, ischemia in the
LCX region impaired the response of microvessels to the
endothelium-dependent agent ADP compared with mi-
crovessels in the normally perfused LAD myocardium.
Intracoronary infusion of VEGF fully restored the responses
of the LCX region microvasculature to ADP (Fig. 5). This
salutary effect of VEGF administration was partially
blocked by the pretreatment with L-NAME at the time of
VEGF infusion. Intravenous administration of VEGF
failed to restore microvascular function in the LCX myo-
cardium (data not shown). No differences were observed in
the endothelium-independent responses of the microvascu-
lature.
DISCUSSION
Background. Vascular endothelial growth factor is a potent
angiogenic agent that might be clinically useful in the
management of syndromes of myocardial ischemia.
VEGF165 promotes angiogenesis in both cell culture models
(20) and in vivo models including the heart (8–10,21).
Furthermore, VEGF165 plays a key role in embryonic
vasculogenesis because disruption of even a single copy of
the gene is sufficient to induce early lethality (22,23). The
mechanism of VEGF-induced angiogenic activity is not
Figure 2. Regional blood flow change in the ischemic area between
mid-study and final study at rest with individual data and mean and
standard deviation. Increase in regional blood flow over time at rest was
significant in the intracoronary VEGF group without L-NAME (*p 5
0.006).
Figure 3. Change in global ventricular function (fractional shortening)
from mid-study to final study with individual data and mean and standard
deviation. The asterisk indicates a significant decrease in global LV
function at rest (p 5 0.002) in the control group. Con 5 control group,
slowIV: intravenous VEGF 0.05 mg/kg/min, fastIV: intravenous VEGF
0.25 mg/kg/min, IC: intracoronary VEGF 0.25 mg/kg/min, IC1LN:
intracoronary VEGF 0.25 mg/kg/min plus L-NAME.
Figure 4. Change in regional LV wall thickening from mid-study to final
study with individual data and mean and standard deviation. In none of the
groups did the indexed regional wall thickening change significantly over
time. Con 5 control group, slowIV: intravenous VEGF 0.05 mg/kg/min,
fastIV: intravenous VEGF 0.25 mg/kg/min, IC: intracoronary VEGF 0.25
mg/kg/min, IC1LN: intracoronary VEGF 0.25 mg/kg/min plus
L-NAME.
Figure 5. Endothelium dependent elaxation of microvessels. Relaxation
was induced by adenosine diphosphate (ADP). Microvessels were taken
from the ischemic area (LCX, dotted lines) and the normal area (LAD,
uninterrupted lines) from pigs that were treated with intracoronary
VEGF, intracoronary VEGF 1 L-NAME or vehicle. * LCX microvessels
from intracoronary VEGF 1 L-NAME treated animals had a lower
response to maximum dose of ADP than the intracoronary VEGF group
(p 5 0.011).
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clear but is thought to involve stimulation of vessel perme-
ability (24), release of NO (13), promotion of monocyte/
macrophage chemotaxis (25) and induction of expression of
a number of angiogenesis-promoting proteases (26).
This multitude of actions might contribute to its thera-
peutic effect but also harbors a potential for dose-limiting
side effects. For example, in early preclinical and clinical
trials, VEGF165 induced an NO-mediated hypotension.
Therefore, the present study was undertaken to investigate
how, in the setting of chronic myocardial ischemia, thera-
peutic and toxic effects are affected by the mode of delivery
and by inhibition of NO synthase activity. Single intracoro-
nary or intravenous injection of VEGF would offer relative
ease of use and appeal to a broader segment of the patient
population than the currently used intramyocardial injection
during bypass surgery. In the case of VEGF165, a bolus
intracoronary administration (10) or local intracoronary
delivery (9) in a porcine model resulted in a significant
improvement in myocardial perfusion and function but was
associated with profound and sometimes lethal hypotension
(10). Therefore, we have chosen to administer VEGF165 by
either intracoronary infusion or intravenous infusion over
40 min. To assess the rate of infusion on hemodynamics and
angiogenic potency, another group of animals was given the
same total amount of VEGF165 over 200 min by an
intravenous infusion.
Because VEGF165 hypotension is predominantly NO-
mediated, we have also explored the utility of short-term
NO synthase inhibition with L-NAME. L-NAME is an
irreversible inhibitor capable of inactivating all three NO
synthases (nNOS, eNOS and iNOS) and was shown to
eliminate ;80% of VEGF-induced vasodilation (11,27).
The effect of single L-NAME administration on the an-
giogenic efficacy of VEGF165 has not been studied.
Animal model. We chose a porcine ameroid model for this
study because of its several unique benefits. First, the
application of an occluder results in reproducible and
gradual occlusion of the coronary artery, with reduced blood
flow to the LCX territory. This reduction in coronary flow
leads to a significant reduction in regional myocardial
function and an equally significant reduction in microvas-
cular responsiveness to endothelium-dependent vasodilators
such as ADP. Furthermore, these changes occur in the
setting of minimal (typically ,5%) myocardial necrosis and
remain stable over time. The latter attribute is especially
important for longitudinal testing of angiogenic agents.
This study was not powered to permit between-group
comparisons, and we therefore cannot directly compare
treatment groups. However, the chosen analysis allows us to
support statements on the efficacy of each delivery method
separately.
Intracoronary VEGF improves regional blood flow. In
the present study, regional myocardial blood flow as mea-
sured by the colored microsphere method and angiography
was consistently improved by intracoronary VEGF165.
Moreover, pretreatment with a single dose of L-NAME
sufficient to inhibit VEGF-induced systemic hypotension
did not inhibit the ability of VEGF165 to enhance regional
blood flow at stress in this model. Nv-nitro-L-arginine
methyl ester hydrochloride pretreatment, however, did
prevent VEGF-mediated restoration of endothelium-
dependent microvascular reactivity, possibly because of the
irreversible nature of NOS inhibition by L-NAME and the
considerable half-life of L-NOARG, the active metabolite
of L-NAME (28).
Although half of the intracoronary VEGF dose was given
into the right coronary artery, right-to-left collateralization
did not improve, which is consistent with previous experi-
ments in this model (6,9,11,29). The development of
right-to-left collaterals is probably dependent on anatomic
variations and is not treatment related.
Assessment of regional myocardial function by echocar-
diography. Despite the improvement in myocardial perfu-
sion, evaluation of regional LV function demonstrated
continued abnormality (i.e., low target over normal wall
thickening index) in both IC groups. Alternatively, this
absence of functional improvement could suggest either that
restoration of the coronary flow was not complete or that
the echocardiographic assessment is less sensitive and/or
accurate than the magnetic resonance imaging employed in
our prior study of intracoronary VEGF165 (9). Because the
same model was used in both of our studies with intracoro-
nary VEGF, we suggest that echocardiographic assessment
of ventricular function in our hands might not have been
sensitive enough to pick up modest changes in ventricular
function.
Intravenous VEGF165 is ineffective. Intravenous delivery
of VEGF165, whether given as a 40 or 200 min infusion, was
not effective with regard to most end points studied.
Although there was a statistically significant increase in the
coronary collateral index, the absence of any improvement
in microsphere-measured myocardial blood flow, regional
LV function or microvascular function strongly argues
against effectiveness of this mode of delivery. This result is
similar to findings in the study of Lazarous et al. (7) in
which daily intra-atrial injections of 0.72 mg rhVEGF165
from 10 to 16 days or 17 to 23 days after ameroid placement
were also ineffective.
VEGF165-induced hypotension. Both IC and IV infu-
sions induced equally profound systemic hypotension that
was not reduced by decreasing the rate of infusion. At the
same time, L-NAME effectively abolished the hypotensive
effect of VEGF165. Hypotension is a serious acute side effect
of systemic or intracoronary VEGF165 administration (10–
12,27), and in a number of in vivo studies, this effect was
shown to be mediated by nitric oxide. VEGF165 induces
acute NO release, and chronic VEGF165 administration
leads to induction of both eNOS (30) and iNOS (31)
expression. The currently reported successful use of a single
L-NAME dose prior to VEGF165 infusion to inhibit
VEGF-induced hypotension while retaining its angiogenic
effect may therefore be of clinical importance as the total
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VEGF165 dose that can be administered is no longer limited
by this side effect.
Clinical implications. The differences between this study
and the recent Phase II clinical trial (3) might offer new
insight into the pharmacokinetics and the role of the
mode of VEGF165 delivery in the coronary circulation.
To avoid hypotension, the dose in the clinical trial was
limited to approximately 80 mg VEGF165 given intra-
coronary as opposed to 400 mg in our study. In the
clinical study, intravenous VEGF165 dosages were given
3, 6 and 9 days later, but our results show no effect of
intravenously delivered VEGF165, so they probably did
not contribute to the overall effective VEGF165 dose. As
intravenous delivery is ineffective, the efficacy of intra-
coronary delivery probably depends on the first-pass
effect, the magnitude of which is unknown for VEGF165
in the coronary circulation. It is therefore also important
that in the clinical trial, rhVEGF165 was delivered in a
relatively small part of the coronary system and not
directly to the occluded regions, whereas in our study, the
entire coronary circulation was covered, and half of the
dose was directed at the occluded artery. Thus, it is
possible that intracoronary rhVEGF165, when given at a
sufficiently high dose and directed to the target areas
including the occlusions, is effective as a therapeutic
angiogenic growth factor in myocardial ischemia. The
hypotensive side effects of such a high dose rhVEGF165
can be inhibited by a single L-NAME dose.
Conclusions. Single intracoronary infusion of 0.25 mg/kg/
min of rhVEGF165 results in a significant improvement in
collateralization of chronically ischemic myocardium and
concomitant increase in myocardial blood flow. Nv-nitro-
L-arginine methyl ester hydrochloride at a dose that is
sufficiently high to block VEGF-induced hypotension
most likely does not affect VEGF-induced angiogenesis.
Intracoronary VEGF 10 mg/kg did not improve LV func-
tion. Single intravenous infusion of the same amount of
rhVEGF165 was ineffective with regard to restoration of
coronary perfusion or myocardial function.
Reprint requests and correspondence: Dr. Mark J Post, Angio-
genesis Research Center, Beth Israel Deaconess Medical Center,
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